Zoetis (ZTS) Stock Forecast, Price Target & Predictions
ZTS Stock Forecast
Zoetis stock forecast is as follows: an average price target of $227.71 (represents a 28.68% upside from ZTS’s last price of $176.96) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
ZTS Price Target
The average price target for Zoetis (ZTS) is $227.71 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $254.00 to $195.00. This represents a potential 28.68% upside from ZTS's last price of $176.96.
ZTS Analyst Ratings
According to 8 Wall Street analysts, Zoetis's rating consensus is 'Buy'. The analyst rating breakdown for ZTS stock is 0 'Strong Buy' (0.00%), 7 'Buy' (87.50%), 1 'Hold' (12.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Zoetis Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 07, 2024 | Balaji Prasad | Barclays | - | - | 30.61% | 36.75% |
| Aug 05, 2024 | Jonathan Block | Stifel Nicolaus | - | - | 13.44% | 13.02% |
| Apr 16, 2024 | David Westenberg | Piper Sandler | - | - | 30.20% | 10.19% |
| Apr 02, 2024 | Jonathan Block | Stifel Nicolaus | - | - | 16.75% | 10.19% |
| Nov 15, 2022 | Morgan Stanley | - | - | 65.06% | 40.14% | |
| Feb 21, 2022 | David Steinberg | Jefferies | - | - | 32.76% | 43.54% |
| Aug 25, 2021 | Jasper Hellweg | Argus Research | - | - | 10.37% | 27.15% |
| Aug 09, 2021 | Katie Tryhane | Credit Suisse | - | - | 15.49% | 29.97% |
The latest Zoetis stock forecast, released on Aug 07, 2024 by Balaji Prasad from Barclays, set a price target of $242.00, which represents a 30.61% increase from the stock price at the time of the forecast ($185.29), and a 36.75% increase from ZTS last price ($176.96).
Zoetis Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $208.00 |
| Last Closing Price | $176.96 | $176.96 | $176.96 |
| Upside/Downside | -100.00% | -100.00% | 17.54% |
In the current month, the average price target of Zoetis stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Zoetis's last price of $176.96. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 11, 2024 | Stifel Nicolaus | Buy | Buy | Hold |
| Sep 20, 2024 | William Blair | Market Perform | Market Perform | Hold |
| Sep 18, 2024 | Stifel Nicolaus | Buy | Buy | Hold |
| Aug 14, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 07, 2024 | Barclays | Overweight | Overweight | Hold |
| Jul 25, 2024 | BTIG | Buy | Initialise | |
| Apr 16, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Apr 12, 2024 | William Blair | Outperform | Outperform | Hold |
| Feb 13, 2024 | William Blair | Outperform | Outperform | Hold |
| Feb 15, 2023 | RBC Capital | Outperform | Upgrade |
Zoetis's last stock rating was published by Stifel Nicolaus on Oct 11, 2024. The company gave ZTS a "Buy" rating, the same as its previous rate.
Zoetis Financial Forecast
Zoetis Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $2.21B | $2.15B | $2.18B | $2.00B | $2.04B | $2.00B | $2.05B | $1.99B | $1.97B | $1.99B | $1.95B | $1.87B | $1.81B | $1.79B | $1.55B | $1.53B | $1.67B | $1.58B |
| Avg Forecast | $2.62B | $2.67B | $2.65B | $2.43B | $2.43B | $2.47B | $2.46B | $2.27B | $2.31B | $2.29B | $2.31B | $2.15B | $2.19B | $2.17B | $2.16B | $2.01B | $2.00B | $2.08B | $2.03B | $1.98B | $1.93B | $1.93B | $1.83B | $1.72B | $1.74B | $1.63B | $1.35B | $1.50B | $1.64B | $1.58B |
| High Forecast | $2.67B | $2.72B | $2.70B | $2.48B | $2.47B | $2.51B | $2.50B | $2.33B | $2.33B | $2.29B | $2.31B | $2.16B | $2.20B | $2.19B | $2.19B | $2.05B | $2.04B | $2.08B | $2.03B | $1.98B | $1.93B | $1.93B | $1.83B | $1.72B | $1.74B | $1.63B | $1.35B | $1.50B | $1.64B | $1.58B |
| Low Forecast | $2.57B | $2.62B | $2.60B | $2.38B | $2.38B | $2.42B | $2.41B | $2.19B | $2.30B | $2.29B | $2.31B | $2.15B | $2.18B | $2.16B | $2.11B | $1.97B | $1.96B | $2.08B | $2.03B | $1.98B | $1.93B | $1.93B | $1.83B | $1.72B | $1.74B | $1.63B | $1.35B | $1.50B | $1.64B | $1.58B |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 8 | 8 | 9 | 12 | 7 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 0.99% | 1.01% | 0.99% | 1.02% | 0.96% | 1.01% | 1.00% | 1.02% | 1.03% | 1.07% | 1.09% | 1.04% | 1.10% | 1.14% | 1.02% | 1.02% | 1.00% |
Zoetis's average Quarter revenue forecast for Mar 24 based on 3 analysts is $2.15B, with a low forecast of $2.15B, and a high forecast of $2.16B. ZTS's average Quarter revenue forecast represents a -2.69% decrease compared to the company's last Quarter revenue of $2.21B (Dec 23).
Zoetis EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 8 | 8 | 9 | 12 | 7 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $599.00M | $836.00M | $975.00M | $818.00M | $691.00M | $853.00M | $761.00M | $907.00M | $678.00M | $825.00M | $806.00M | $854.00M | $124.00M | $770.00M | $652.00M | $660.00M | $602.00M | $691.00M |
| Avg Forecast | $1.08B | $1.09B | $1.09B | $997.08M | $995.85M | $1.01B | $1.01B | $932.15M | $947.67M | $938.12M | $947.86M | $994.18M | $896.93M | $890.43M | $883.65M | $903.80M | $714.73M | $805.33M | $783.03M | $821.64M | $746.94M | $746.10M | $705.65M | $663.30M | $671.73M | $629.64M | $523.72M | $590.93M | $632.54M | $609.74M |
| High Forecast | $1.09B | $1.11B | $1.11B | $1.01B | $1.01B | $1.03B | $1.02B | $956.79M | $955.84M | $938.72M | $947.86M | $1.19B | $901.02M | $898.38M | $899.11M | $1.08B | $857.67M | $805.33M | $783.03M | $985.97M | $746.94M | $746.10M | $705.65M | $795.96M | $671.73M | $629.64M | $523.72M | $709.12M | $632.54M | $609.74M |
| Low Forecast | $1.05B | $1.07B | $1.06B | $976.59M | $975.38M | $990.23M | $986.03M | $899.30M | $943.58M | $937.52M | $947.86M | $795.35M | $892.83M | $885.34M | $865.49M | $723.04M | $571.78M | $805.33M | $783.03M | $657.31M | $746.94M | $746.10M | $705.65M | $530.64M | $671.73M | $629.64M | $523.72M | $472.74M | $632.54M | $609.74M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.67% | 0.94% | 1.10% | 0.91% | 0.97% | 1.06% | 0.97% | 1.10% | 0.91% | 1.11% | 1.14% | 1.29% | 0.18% | 1.22% | 1.24% | 1.12% | 0.95% | 1.13% |
3 analysts predict ZTS's average Quarter EBITDA for Mar 24 to be $994.18M, with a high of $1.19B and a low of $795.35M. This is 65.97% upper than Zoetis's previous annual EBITDA (Dec 23) of $599.00M.
Zoetis Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 8 | 8 | 9 | 12 | 7 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $525.00M | $596.00M | $671.00M | $552.00M | $461.00M | $529.00M | $529.00M | $595.00M | $413.00M | $552.00M | $512.00M | $559.00M | $357.00M | $479.00M | $377.00M | $423.00M | $384.00M | $433.00M |
| Avg Forecast | $783.04M | $848.05M | $825.37M | $715.02M | $698.74M | $758.22M | $751.61M | $659.22M | $622.32M | $660.46M | $673.49M | $660.94M | $596.98M | $615.13M | $593.12M | $600.85M | $436.42M | $563.45M | $552.63M | $546.23M | $439.07M | $506.21M | $494.89M | $434.17M | $393.78M | $415.50M | $292.90M | $378.73M | $400.90M | $402.52M |
| High Forecast | $800.86M | $867.34M | $844.15M | $731.29M | $714.64M | $775.48M | $768.71M | $672.77M | $644.86M | $679.75M | $673.51M | $793.13M | $605.96M | $637.74M | $619.33M | $721.02M | $523.71M | $571.66M | $565.69M | $655.48M | $439.07M | $506.21M | $511.78M | $521.01M | $393.78M | $415.50M | $292.90M | $454.48M | $400.90M | $402.52M |
| Low Forecast | $762.12M | $825.39M | $803.32M | $695.92M | $680.08M | $737.97M | $731.53M | $645.68M | $613.30M | $641.18M | $673.47M | $528.75M | $592.49M | $601.56M | $566.91M | $480.68M | $349.14M | $555.23M | $539.57M | $436.98M | $439.07M | $506.21M | $478.01M | $347.34M | $393.78M | $415.50M | $292.90M | $302.99M | $400.90M | $402.52M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.88% | 0.97% | 1.13% | 0.92% | 1.06% | 0.94% | 0.96% | 1.09% | 0.94% | 1.09% | 1.03% | 1.29% | 0.91% | 1.15% | 1.29% | 1.12% | 0.96% | 1.08% |
Zoetis's average Quarter net income forecast for Mar 24 is $660.94M, with a range of $528.75M to $793.13M. ZTS's average Quarter net income forecast represents a 25.89% increase compared to the company's last Quarter net income of $525.00M (Dec 23).
Zoetis SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 8 | 8 | 9 | 12 | 7 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $565.00M | $525.00M | $556.00M | $505.00M | $514.00M | $501.00M | $529.00M | $465.00M | $593.00M | $504.00M | $495.00M | $409.00M | $520.00M | $424.00M | $393.00M | $389.00M | $472.00M | $391.00M |
| Avg Forecast | $670.84M | $682.79M | $677.38M | $621.76M | $621.00M | $630.45M | $627.77M | $581.27M | $590.95M | $585.00M | $591.07M | $516.53M | $559.31M | $555.26M | $551.03M | $469.57M | $625.12M | $532.50M | $517.76M | $426.89M | $493.89M | $493.34M | $466.59M | $317.67M | $444.16M | $416.33M | $346.29M | $348.29M | $418.25M | $403.17M |
| High Forecast | $682.58M | $694.74M | $689.23M | $632.64M | $631.86M | $641.48M | $638.76M | $596.64M | $596.05M | $585.37M | $591.07M | $619.84M | $561.86M | $560.22M | $560.67M | $563.49M | $750.14M | $532.50M | $517.76M | $512.26M | $493.89M | $493.34M | $466.59M | $381.20M | $444.16M | $416.33M | $346.29M | $417.95M | $418.25M | $403.17M |
| Low Forecast | $657.05M | $668.76M | $663.46M | $608.99M | $608.23M | $617.49M | $614.87M | $560.79M | $588.40M | $584.62M | $591.07M | $413.22M | $556.76M | $552.08M | $539.71M | $375.66M | $500.10M | $532.50M | $517.76M | $341.51M | $493.89M | $493.34M | $466.59M | $254.14M | $444.16M | $416.33M | $346.29M | $278.63M | $418.25M | $403.17M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 0.95% | 1.01% | 1.08% | 0.82% | 0.94% | 1.02% | 1.09% | 1.20% | 1.02% | 1.06% | 1.29% | 1.17% | 1.02% | 1.13% | 1.12% | 1.13% | 0.97% |
Zoetis's average Quarter SG&A projection for Mar 24 is $516.53M, based on 3 Wall Street analysts, with a range of $413.22M to $619.84M. The forecast indicates a -8.58% fall compared to ZTS last annual SG&A of $565.00M (Dec 23).
Zoetis EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 3 | 3 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 8 | 8 | 9 | 12 | 7 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $1.14 | $1.29 | $1.45 | $1.19 | $0.99 | $1.13 | $1.13 | $1.26 | $0.87 | $1.16 | $1.08 | $1.18 | $0.75 | $1.01 | $0.79 | $0.89 | $0.81 | $0.91 |
| Avg Forecast | $1.73 | $1.87 | $1.82 | $1.58 | $1.54 | $1.67 | $1.66 | $1.45 | $1.37 | $1.46 | $1.49 | $1.35 | $1.32 | $1.36 | $1.31 | $1.25 | $1.15 | $1.24 | $1.21 | $1.23 | $0.96 | $1.11 | $1.09 | $1.04 | $0.86 | $0.91 | $0.64 | $0.86 | $0.88 | $0.88 |
| High Forecast | $1.77 | $1.91 | $1.86 | $1.61 | $1.58 | $1.71 | $1.70 | $1.48 | $1.42 | $1.50 | $1.49 | $1.35 | $1.34 | $1.41 | $1.37 | $1.27 | $1.18 | $1.25 | $1.24 | $1.23 | $0.96 | $1.11 | $1.12 | $1.04 | $0.86 | $0.91 | $0.64 | $0.86 | $0.88 | $0.88 |
| Low Forecast | $1.68 | $1.82 | $1.77 | $1.53 | $1.50 | $1.63 | $1.61 | $1.42 | $1.35 | $1.41 | $1.49 | $1.34 | $1.31 | $1.33 | $1.25 | $1.21 | $1.12 | $1.22 | $1.18 | $1.23 | $0.96 | $1.11 | $1.05 | $1.04 | $0.86 | $0.91 | $0.64 | $0.86 | $0.88 | $0.88 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.87% | 0.95% | 1.11% | 0.96% | 0.86% | 0.91% | 0.93% | 1.02% | 0.90% | 1.04% | 1.00% | 1.14% | 0.87% | 1.11% | 1.23% | 1.03% | 0.92% | 1.03% |
According to 3 Wall Street analysts, Zoetis's projected average Quarter EPS for Mar 24 is $1.35, with a low estimate of $1.34 and a high estimate of $1.35. This represents a 18.06% increase compared to ZTS previous annual EPS of $1.14 (Dec 23).
Zoetis Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EBS | Emergent BioSolutions | - | - | 443.25% | Buy |
| ASRT | Assertio | - | - | 206.38% | Buy |
| ELAN | Elanco Animal Health | - | - | 98.35% | Buy |
| AMPH | Amphastar Pharmaceuticals | - | - | 45.18% | Buy |
| ALVO | Alvotech | - | - | 33.44% | Hold |
| ZTS | Zoetis | - | - | 28.68% | Buy |
| BHC | Bausch Health Companies | - | - | 25.47% | Hold |
| CTLT | Catalent | - | - | 21.76% | Hold |
| NBIX | Neurocrine Biosciences | - | - | 17.27% | Buy |
| TEVA | Teva Pharmaceutical Industries | - | - | 16.82% | Buy |
| ITCI | Intra-Cellular Therapies | - | - | 10.28% | Buy |
| VTRS | Viatris | - | - | 2.84% | Hold |
| PETQ | PetIQ | - | - | 0.06% | Buy |
| HLN | Haleon | - | - | -5.18% | Buy |